약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 3.

Table. 3. Signal detection of GLP-1 RAs using disproportionality analysis when restricted to reports by physician in WHO-UMC VigiBase® from April 2005 to January 2023
Cases of GLP-1 RA Non-cases of GLP-1 RA ROR (95% CI) Signal
Biliary tract disorders*
America 26 11,614 2.79 (1.79-4.35) O
Europe 57 21,012 0.63 (0.48-0.83) X
Asia 13 2,899 1.65 (0.94-2.90) X
Other regions 0 358 N/A N/A
Gallbladder-related disorders*
America 147 11,493 11.31 (8.82-14.49) O
Europe 119 20,950 7.06 (5.35-9.31) O
Asia 37 2,875 5.32 (3.71-7.62) O
Other regions 1 357 1.69 (0.22-13.01) X

Abbreviations: ROR, Reporting Odds Ratio; CI, Confidence Interval; WHO-UMC, World Health Organization-Uppsala Monitoring Centre

*The Adverse Events of interest are defined using Standardized MedDRA Queries (SMQ)

Safety signals detection with ROR were assessed as AEs where thresholds of ROR were greater than one.

Yakhak Hoeji 2024;68:112-20 https://doi.org/10.17480/psk.2024.68.2.112
© 2024 Yakhak Hoeji